CD8A and non-small cell lung carcinoma: These latter results are in line with reports by Jackson et al.63 and Leclerc et al.19 who found that ~10% of CD8+ TILs from melanoma patients and 14% of non-small-cell lung cancer patients, respectively, were NRP1 positive.